Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Medical Oncology

• Publication date

  2011-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12032-010-9669-yPMID 20809183
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib

  2010cited by this paper
• Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now?

  2010cited by this paper
• Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.

  2010influential reference
• The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization

  2010cited by this paper
• Viral hepatitis and HIV co-infection.

  2010cited by this paper
• Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma

  2009cited by this paper
• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Anti-HIV drugs for cancer therapeutics: back to the future?

  2009cited by this paper
• Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells

  2009cited by this paper
• Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study.

  2009cited by this paper
• The pathogenesis of liver disease in the setting of HIV–hepatitis B virus coinfection

  2009cited by this paper
• Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma

  2008cited by this paper
• Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report

  2008cited by this paper
• Pivotal role of mTOR signaling in hepatocellular carcinoma.

  2008cited by this paper
• Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

  2008cited by this paper
• Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008influential reference
• Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer

  2006cited by this paper
• Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

  2006cited by this paper
• Management of hepatocellular carcinoma

  2005cited by this paper
• Prevention of hepatitis B virus-related hepatocellular carcinoma.

  2004cited by this paper

• Complete Response to Sorafenib in an HCV/HIV Coinfected Patient with Infiltrative Hepatocellular Carcinoma and Portal Vein Thrombosis

  2025cites this paper
• Case report: Complete response after transcatheter arterial chemoembolization combined with donafenib plus tislelizumab therapy for hepatocellular carcinoma with main trunk portal vein tumor thrombus in a patient coinfected with HIV and HBV

  2024cites this paper
• Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV

  2022cites this paper
• A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario

  2021cites this paper
• Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research

  2021cites this paper
• Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment

  2021cites this paper
• Long-term sustained complete response with off-therapy to sorafenib in advanced hepatocellular carcinoma: a case report

  2020cites this paper
• Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report.

  2020cites this paper
• Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib.

  2020influential citation
• Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell)

  2018cites this paper
• Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature

  2017cites this paper
• A Phase Ib Study of Sorafenib (BAY 43‐9006) in Patients with Kaposi Sarcoma

  2017cites this paper
• Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review

  2017cites this paper
• Complete response to short‐term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases

  2016cites this paper
• Deteriorated portal flow may cause liver failure in patients with hepatocellular carcinoma being treated with sorafenib.

  2016cites this paper
• Long-Term Maintenance of Complete Response after Sorafenib Treatment for Multiple Lung Metastases from Hepatocellular Carcinoma

  2015cites this paper
• Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy

  2015influential citation
• Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib

  2015cites this paper
• Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.

  2014cites this paper
• Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: Could we stop the treatment? About four cases

  2014cites this paper
• Metastatic hepatocellular carcinoma: when surgery and successive palliative treatments lead to remission.

  2014cites this paper
• British HIV Association guidelines for HIV‐associated malignancies 2014

  2014cites this paper
• Serial changes of clinical parameters in a patient with advanced hepatocellular carcinoma with portal vein thrombosis achieving complete response after treatment with sorafenib

  2014cites this paper
• Characteristics of 18 patients with hepatocellular carcinoma who obtained a complete response after treatment with sorafenib

  2014cites this paper
• Hepatocellular carcinoma in HIV positive patients.

  2014cites this paper
• Complete remission of advanced hepatocellular carcinoma by sorafenib: A case report.

  2013cites this paper
• A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.

  2013cites this paper
• Sustained Remission Over 36 Months of Advanced Hepatocellular Carcinoma After Short-Term Sorafenib Therapy

  2013cites this paper
• Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients

  2013cites this paper
• Letter: sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV‐infected patients

  2013cites this paper
• Rapid long-lasting biochemical and radiological response to sorafenib in a case of advanced hepatocellular carcinoma

  2013cites this paper
• Complete Response after Short-Term Sorafenib Treatment in a Patient with Lymph Node Metastasis of Hepatocellular Carcinoma

  2012cites this paper
• Treatment of Hepatocellular Carcinoma with Sorafenib – Focus on Special Populations and Adverse Event Management

  2012cites this paper
• Complete clinical response of a patient with lymph node and pulmonary metastatic hepatocellular carcinoma to very low-dose sorafenib (Nexavar®) therapy

  2012cites this paper
• Treatment of Recurrent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-Infected patient in HAART: A Case Report

  2012influential citation
• HIV and viral hepatitis coinfections: advances and challenges

  2012cites this paper
• AFP Measurement in Monitoring Treatment Response of Advanced Hepatocellular Carcinoma to Sorafenib: Case Report and Review of the Literature

  2011cites this paper
• Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report

  2011cites this paper
• Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies

  2011cites this paper